Urinary and plasma CNP have prognostic value in Aute Decopensated HF: Study
Elevations in both urinary and plasma C-type natriuretic peptides contribute independent prognostic value for the prediction of adverse outcomes in Acute Decompensated Heart failure (ADHF), suggests a study published in the JACC: Heart Failure.
CNP is a protective hormone that is synthesized in the kidney and endothelium and possesses anti-remodelling properties. Urinary and plasma CNP levels are elevated in pathophysiological conditions; however, their regulation and prognostic value in heart failure (HF) is unclear.
A group of researchers from U.S.A conducted a study to characterize urinary and plasma C-type natriuretic peptide (CNP) in acute decompensated heart failure (ADHF) to define their relationship with clinical variables and to determine whether urinary and plasma CNP together add prognostic value.
Urinary and plasma CNP were measured in 109 healthy subjects and 208 patients with ADHF; the 95th percentile of CNP values from healthy subjects established the normal contemporary cutoffs. Patients with ADHF were stratified based on urinary and plasma CNP levels for clinical characterization and the assessment of risk for adverse outcomes.
The results of the study are as follows:
· There was no significant correlation between urinary and plasma CNP in both cohorts.
· Urinary and plasma CNP were significantly elevated in patients with ADHF, and both increased with disease severity and were positively correlated with plasma N-terminal pro–B-type natriuretic peptide (NT-proBNP).
· Of the patients with ADHF, 23% had elevations in both urinary and plasma CNP, whereas 24% had normal CNP levels.
· During a median follow-up of 3 years, patients with elevated urinary and plasma CNP had a significantly higher risk of rehospitalization and/or death (HR: 1.79; P = 0.03) and rehospitalization (HR: 2.16; P = 0.01) after adjusting for age, sex, left ventricular ejection fraction, renal function, and plasma NT-proBNP.
· The C-statistic and integrated discrimination analyses further supported that the addition of urinary and plasma CNP to established risk models improved the prediction of adverse outcomes in patients with ADHF.
Thus, the researchers concluded that urinary and plasma CNP are differentially regulated in ADHF, and elevations in both provided independent prognostic value for predicting adverse outcomes.
References:
Prognostic Value of Urinary and Plasma CNP in Acute Decompensated HF by Ma X et. al published in the JACC: Heart Failure.
https://www.jacc.org/doi/10.1016/j.jchf.2021.04.013
